Search details
1.
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program.
Br J Cancer
; 129(5): 852-860, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37468569
2.
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
Br J Cancer
; 129(4): 706-720, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37420000
3.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Article
in English
| MEDLINE | ID: mdl-36239405
4.
Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis.
Breast Cancer Res Treat
; 197(2): 405-416, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36396774
5.
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study.
Breast Cancer Res Treat
; 199(1): 35-46, 2023 May.
Article
in English
| MEDLINE | ID: mdl-36859649
6.
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Lancet
; 395(10237): 1613-1626, 2020 05 23.
Article
in English
| MEDLINE | ID: mdl-32580883
7.
Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Lancet
; 390(10099): 1048-1060, 2017 Sep 09.
Article
in English
| MEDLINE | ID: mdl-28779963
8.
Breast cancer radiation therapy - Authors' reply.
Lancet
; 396(10262): 1559-1560, 2020 11 14.
Article
in English
| MEDLINE | ID: mdl-33189173
9.
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Lancet Oncol
; 15(1): 114-22, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24332514
10.
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.
Future Oncol
; 10(2): 219-31, 2014 Feb.
Article
in English
| MEDLINE | ID: mdl-24490608
11.
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Lancet Oncol
; 14(10): 989-98, 2013 Sep.
Article
in English
| MEDLINE | ID: mdl-23902874
12.
Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative Breast Cancer.
Clin Cancer Res
; 30(4): 895-903, 2024 02 16.
Article
in English
| MEDLINE | ID: mdl-38078899
13.
First-line avelumab plus chemotherapy in patients with advanced solid tumors: results from the phase 1b/2 JAVELIN Chemotherapy Medley study.
Cancer Res Commun
; 2024 Apr 26.
Article
in English
| MEDLINE | ID: mdl-38669053
14.
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
Health Technol Assess
; 27(25): 1-176, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37991196
15.
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
Breast Cancer Res Treat
; 133(3): 1057-65, 2012 Jun.
Article
in English
| MEDLINE | ID: mdl-22418700
16.
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer.
Breast
; 66: 69-76, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-36194950
17.
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
JAMA Oncol
; 7(12): 1791-1799, 2021 12 01.
Article
in English
| MEDLINE | ID: mdl-34617955
18.
Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.
J Clin Oncol
; 38(28): 3261-3272, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-32663119
19.
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
J Clin Oncol
; 38(5): 423-433, 2020 02 10.
Article
in English
| MEDLINE | ID: mdl-31841354
20.
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
JAMA Oncol
; 5(10): 1473-1478, 2019 10 01.
Article
in English
| MEDLINE | ID: mdl-31369045